A New Business Model For Deprioritized Clinical Trials
Executive Summary
While the pharmaceutical industry faces many issues, a lack of potential assets is not one of them. A structured approach to developing those products, which may have been deprioritized because of company resources or do not promise the ROI needed by external investors, is being explored to the benefit of all parties.